ACE2 and cancer: Nonetheless, postponing cancer screening programs can enhance the morbidity and mortality risk attributable to GI malignancies, rendering these patients also more susceptible to COVID-19, since ACE-2 expression in enterocytes progressively increases with malignancy stage.